JP2014524902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524902A5 JP2014524902A5 JP2014515968A JP2014515968A JP2014524902A5 JP 2014524902 A5 JP2014524902 A5 JP 2014524902A5 JP 2014515968 A JP2014515968 A JP 2014515968A JP 2014515968 A JP2014515968 A JP 2014515968A JP 2014524902 A5 JP2014524902 A5 JP 2014524902A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding fragment
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 210000002889 endothelial cell Anatomy 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 239000003053 toxin Substances 0.000 claims description 15
- 231100000765 toxin Toxicity 0.000 claims description 15
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 241000193738 Bacillus anthracis Species 0.000 claims description 6
- 101710194807 Protective antigen Proteins 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 108010044540 auristatin Proteins 0.000 claims description 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 4
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 4
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 4
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 4
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 12
- 101710125943 Anthrax toxin receptor 1 Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496986P | 2011-06-14 | 2011-06-14 | |
| US201161496737P | 2011-06-14 | 2011-06-14 | |
| US61/496,986 | 2011-06-14 | ||
| US61/496,737 | 2011-06-14 | ||
| PCT/US2012/042315 WO2012174160A1 (en) | 2011-06-14 | 2012-06-13 | Tem8 antibodies, conjugates thereof, and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524902A JP2014524902A (ja) | 2014-09-25 |
| JP2014524902A5 true JP2014524902A5 (enExample) | 2015-07-09 |
Family
ID=47357454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515968A Pending JP2014524902A (ja) | 2011-06-14 | 2012-06-13 | Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9181340B2 (enExample) |
| EP (1) | EP2721071A4 (enExample) |
| JP (1) | JP2014524902A (enExample) |
| CA (1) | CA2837892A1 (enExample) |
| WO (1) | WO2012174160A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
| HK1219980A1 (zh) * | 2013-03-09 | 2017-04-21 | Baylor College Of Medicine | 靶向血管的t细胞疗法 |
| US9862951B2 (en) | 2013-06-14 | 2018-01-09 | Texas Tech University System | RNA interference-based therapeutic against anthrax |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| JP6795877B2 (ja) * | 2013-12-25 | 2020-12-02 | 東京応化工業株式会社 | 表面被覆膜の形成方法及び表面被覆膜を有する太陽電池 |
| US10434174B2 (en) | 2014-06-09 | 2019-10-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells |
| US10799584B2 (en) | 2014-06-09 | 2020-10-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents |
| WO2015191583A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
| WO2015191568A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| WO2015191617A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells |
| WO2015191590A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |
| WO2015191602A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells |
| US10758526B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways |
| JP2019504895A (ja) * | 2016-02-09 | 2019-02-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） |
| CN110234348B (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| CN108707199A (zh) * | 2018-05-29 | 2018-10-26 | 廊坊康宝汇泰生物技术有限公司 | 靶向tem8的嵌合抗原受体t细胞及其应用 |
| WO2024245342A1 (zh) * | 2023-05-31 | 2024-12-05 | 应世生物科技(南京)有限公司 | 一种靶向tem8的抗体或其抗原结合片段及其应用 |
| WO2025179281A1 (en) * | 2024-02-23 | 2025-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of cardiovascular disease with antxr1 antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2810195B1 (fr) | 2000-06-16 | 2002-08-30 | Kuhn Audureau Sa | Machine de coupe pouvant etre accrochee a un tracteur et comprenant un mecanisme de coupe a rotor et couteaux perfectionne |
| AU2001283062A1 (en) | 2000-08-02 | 2002-02-13 | The Johns Hopkins University | Endothelial cell expression patterns |
| ATE360071T1 (de) | 2000-12-05 | 2007-05-15 | Wisconsin Alumni Res Found | Rezeptor für ein toxin aus bacillus anthracis |
| EP1572867B1 (en) | 2001-04-11 | 2014-07-23 | The Johns Hopkins University | Endothelial cell expression patterns |
| US20030220287A1 (en) | 2002-03-28 | 2003-11-27 | Phillips M. Ian | Antisense nucleic acids |
| US20070020271A1 (en) | 2003-03-04 | 2007-01-25 | Beverly Teicher | Endothelial cell specific antibodies and uses thereof |
| JP4411280B2 (ja) * | 2003-10-20 | 2010-02-10 | 帝人ファーマ株式会社 | 骨及び／又は関節疾患関連遺伝子 |
| WO2005081749A2 (en) | 2004-01-23 | 2005-09-09 | Avanir Pharmaceuticals, Inc. | Neutralizing human antibodies to anthraxtoxin |
| ITRM20060337A1 (it) * | 2006-06-27 | 2007-12-28 | Biosoot Srl | Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici |
| CN101591395A (zh) * | 2009-07-13 | 2009-12-02 | 杭州屹源生物技术有限公司 | 抗人肿瘤血管内皮标志分子8胞外区的人源性单链抗体及其应用 |
| WO2012065161A2 (en) | 2010-11-12 | 2012-05-18 | Scott & White Healthcare | Antibodies to tumor endothelial marker 8 |
| WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
-
2012
- 2012-06-13 US US14/126,372 patent/US9181340B2/en active Active
- 2012-06-13 WO PCT/US2012/042315 patent/WO2012174160A1/en not_active Ceased
- 2012-06-13 EP EP12799947.2A patent/EP2721071A4/en not_active Withdrawn
- 2012-06-13 JP JP2014515968A patent/JP2014524902A/ja active Pending
- 2012-06-13 CA CA2837892A patent/CA2837892A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524902A5 (enExample) | ||
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2016533721A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| US11225515B2 (en) | Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2015503909A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2008546780A5 (enExample) | ||
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| EP3768325A1 (en) | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate | |
| JP2017521054A5 (enExample) | ||
| AU2017252574A1 (en) | ALK7 binding proteins and uses thereof | |
| JP2020505075A5 (enExample) | ||
| CA3118542A1 (en) | Cdcp1-targeted therapies | |
| JP2018529328A (ja) | 機能的な癌標的として、糖脂質ではなく糖タンパク質上で発現させたシアリル−ジ−ルイスａ及びそれに対する抗体 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| EP3705495A1 (en) | Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same | |
| TW202108631A (zh) | 一種抗ｃｄ４７抗原結合蛋白及其應用 | |
| RU2024102201A (ru) | Антитело b7h6 и его применение | |
| WO2024213081A1 (zh) | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 | |
| KR20240099186A (ko) | 알파-엽산 수용체에 대한 항체 |